|
4basebio PLC on Monday said its synthetic DNA product has been used in US clinical trials by a ‘global tier one’ pharmaceutical partner. The Cambridge, England-based life sciences firm did not name its partner, explaining it cannot disclose details of the trials at this time. Still, 4basebio noted a supply deal signed with the pharmaceutical firm back in April 2024, for its opDNA template. This is one of four templates the company has developed, which supports mRNA invitro transcription and enables ‘cell-free production of DNA templates.’ According to 4basebio, it is a cheaper, more efficient platform than the current standard of plasmid DNA, alongside having a lower risk of contamination. The partner firm has used 4basebio’s template to develop an mRNA product which has been tested on patients in phase-one and two clinical trials, following investigational new drug approval from the US Food & Drug Administration. 4basebio’s late-phase production site was certified for good manufacturing practice, the minimum standard required by the UK regulator, back in April. The UK firm said that this, coupled with FDA recognition for its partner, strengthens ‘4basebio‘s role as a trusted partner to the global biopharma industry’ and ‘potential to change lives across infectious disease, oncology, and rare genetic disorders.’ Chief Executive Heikki Lanckriet added: ‘This represents another major regulatory milestone for 4basebio and a clear signal of growing industry adoption of synthetic DNA in the use of cell and gene therapies and vaccines.’ 4basebio shares rose 10% to 799.50 pence on Monday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
